TCGA-66-2788-01A-01R-0980-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
- INTERFERON_ALPHA_RESPONSE+0.510
- ANDROGEN_RESPONSE+0.430
- TGF_BETA_SIGNALING+0.430
- INTERFERON_GAMMA_RESPONSE+0.420
- MTORC1_SIGNALING+0.420
- PROTEIN_SECRETION+0.410
- HEDGEHOG_SIGNALING+0.390
- ANGIOGENESIS+0.370
- IL6_JAK_STAT3_SIGNALING+0.350
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.210
- OXIDATIVE_PHOSPHORYLATION-0.170
- MYC_TARGETS_V2-0.130
- BILE_ACID_METABOLISM-0.090
- KRAS_SIGNALING_DN-0.080
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.040
- SPERMATOGENESIS-0.030
- UV_RESPONSE_UP+0.000
- XENOBIOTIC_METABOLISM+0.000
- FATTY_ACID_METABOLISM+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A9T4-01A-11R-A39I-07 | — | — | 0.903 |
| 2 | TCGA-70-6722-01A-11R-1820-07 | — | cohortSQ1 | 0.899 |
| 3 | 2DAB6792-F9AF-4565-BDD5-C9802F3132F4 | — | — | 0.889 |
| 4 | R242 | — | — | 0.889 |
| 5 | TCGA-E7-A97P-01A-11R-A38B-07 | — | — | 0.888 |
| 6 | SRR934782 | — | — | 0.884 |
| 7 | SRR934816 | — | — | 0.883 |
| 8 | TCGA-56-5897-01A-11R-1635-07 | — | cohortSQ1 | 0.875 |
| 9 | TCGA-CN-4734-01A-01R-1436-07 | — | — | 0.874 |
| 10 | SRR934825 | — | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.430 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |